EA202092448A1 - Axl-специфичные антитела для лечения онкологических заболеваний - Google Patents
Axl-специфичные антитела для лечения онкологических заболеванийInfo
- Publication number
- EA202092448A1 EA202092448A1 EA202092448A EA202092448A EA202092448A1 EA 202092448 A1 EA202092448 A1 EA 202092448A1 EA 202092448 A EA202092448 A EA 202092448A EA 202092448 A EA202092448 A EA 202092448A EA 202092448 A1 EA202092448 A1 EA 202092448A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- treatment
- axl
- specific antibodies
- oncological diseases
- cell death
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862655417P | 2018-04-10 | 2018-04-10 | |
| PCT/EP2019/059171 WO2019197506A1 (en) | 2018-04-10 | 2019-04-10 | Axl-specific antibodies for cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202092448A1 true EA202092448A1 (ru) | 2021-03-05 |
Family
ID=66182546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202092448A EA202092448A1 (ru) | 2018-04-10 | 2019-04-10 | Axl-специфичные антитела для лечения онкологических заболеваний |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210070869A1 (https=) |
| EP (1) | EP3774904A1 (https=) |
| JP (1) | JP7681401B2 (https=) |
| CN (1) | CN112218895A (https=) |
| AU (1) | AU2019250443A1 (https=) |
| CA (1) | CA3095986A1 (https=) |
| EA (1) | EA202092448A1 (https=) |
| IL (1) | IL277861A (https=) |
| MA (1) | MA52657A (https=) |
| WO (1) | WO2019197506A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201805534TA (en) | 2016-01-13 | 2018-07-30 | Genmab As | Formulation for antibody and drug conjugate thereof |
| KR102735988B1 (ko) | 2019-02-18 | 2024-12-03 | 일라이 릴리 앤드 캄파니 | 치료 항체 제제 |
| WO2021013746A1 (en) * | 2019-07-19 | 2021-01-28 | Genmab A/S | Axl antibody-drug conjugates for use in treating cancer |
| CA3164706A1 (en) * | 2020-01-14 | 2021-07-22 | Jonathan David SILK | Method of treatment of cancer or tumour |
| AR121441A1 (es) * | 2020-02-28 | 2022-06-08 | Symphogen As | Anticuerpos anti-axl y composiciones |
| EP4259200A1 (en) * | 2020-12-11 | 2023-10-18 | Boehringer Ingelheim International GmbH | Formulation for multi-purpose application |
| JP2024523436A (ja) * | 2021-06-16 | 2024-06-28 | 上海▲シン▼湾生物科技有限公司 | Ａｘｌタンパク質を標的とする抗体及びその抗原結合断片、その調製方法と使用 |
| EP4359439A1 (en) | 2021-06-24 | 2024-05-01 | Yeda Research and Development Co. Ltd | Combination therapy for the treatment of cancer comprising an anti-egfr antibody and an axl-inhibitor |
| IL289525B2 (en) * | 2021-12-30 | 2023-03-01 | B G Negev Technologies And Applications Ltd At Ben Gurion Univ | Conjugated antibodies for cancer treatment |
| WO2024178139A1 (en) * | 2023-02-22 | 2024-08-29 | Resolute Science, Inc. | Compositions and methods for targeting tumor-associated macrophages |
| WO2024178140A1 (en) * | 2023-02-22 | 2024-08-29 | Resolute Science, Inc. | Compositions and methods for targeting tumor-associated macrophages |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| CA2706549A1 (en) | 2007-11-15 | 2009-05-22 | Chugai Seiyaku Kabushiki Kaisha | Monoclonal antibody capable of binding to anexelekto, and use thereof |
| KR20120024763A (ko) | 2009-05-15 | 2012-03-14 | 추가이 세이야쿠 가부시키가이샤 | 항ａｘｌ 항체 |
| BR112012027995A2 (pt) | 2010-06-18 | 2017-01-10 | Genentech Inc | anticorpo e ácido nucleíco isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de um indivíduo com câncer, de um indivíduo possuíndo um distúrbio imune, de inibição da angiogênese e para inibir a ativação constitutiva de axl |
| CN103747803B (zh) | 2011-06-22 | 2016-10-12 | 国家医疗保健研究所 | 抗axl抗体及其用途 |
| AU2012273954A1 (en) | 2011-06-22 | 2014-01-09 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anti-Axl antibodies and uses thereof |
| EP2589609A1 (en) | 2011-11-03 | 2013-05-08 | Pierre Fabre Medicament | Antigen binding protein and its use as addressing product for the treatment of cancer |
| WO2013090776A1 (en) | 2011-12-15 | 2013-06-20 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of axl/gas6 signaling in the treatment of disease |
| US20160106861A1 (en) | 2013-04-26 | 2016-04-21 | Spirogen Sarl | Axl antibody-drug conjugate and its use for the treatment of cancer |
| GB201410825D0 (en) * | 2014-06-18 | 2014-07-30 | Bergenbio As | Anti-axl antibodies |
| MX370807B (es) | 2014-07-11 | 2020-01-08 | Genmab As | Anticuerpos que se unen a axl. |
| JP6931609B2 (ja) * | 2014-12-18 | 2021-09-08 | ベルゲン テクノロジオーヴァーフォリング エイエス | 抗Ａｘｌアンタゴニスト抗体 |
| CN108368171A (zh) * | 2015-07-10 | 2018-08-03 | 根马布股份公司 | 用于癌症治疗的axl特异性抗体-药物缀合物 |
| WO2017146236A1 (ja) * | 2016-02-26 | 2017-08-31 | 小野薬品工業株式会社 | Ａｘｌ阻害剤と免疫チェックポイント阻害剤とを組み合わせて投与することを特徴とする癌治療のための医薬 |
| EP3481868A1 (en) * | 2016-07-08 | 2019-05-15 | Genmab A/S | New dosage regimens for antibody drug conjugates based on anti-axl antibodies |
-
2019
- 2019-04-10 CA CA3095986A patent/CA3095986A1/en active Pending
- 2019-04-10 AU AU2019250443A patent/AU2019250443A1/en not_active Abandoned
- 2019-04-10 JP JP2020555310A patent/JP7681401B2/ja active Active
- 2019-04-10 MA MA052657A patent/MA52657A/fr unknown
- 2019-04-10 CN CN201980037687.7A patent/CN112218895A/zh active Pending
- 2019-04-10 US US17/046,199 patent/US20210070869A1/en active Pending
- 2019-04-10 EA EA202092448A patent/EA202092448A1/ru unknown
- 2019-04-10 WO PCT/EP2019/059171 patent/WO2019197506A1/en not_active Ceased
- 2019-04-10 EP EP19717837.9A patent/EP3774904A1/en active Pending
-
2020
- 2020-10-07 IL IL277861A patent/IL277861A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3774904A1 (en) | 2021-02-17 |
| CA3095986A1 (en) | 2019-10-17 |
| JP7681401B2 (ja) | 2025-05-22 |
| WO2019197506A9 (en) | 2019-12-05 |
| AU2019250443A1 (en) | 2020-10-22 |
| US20210070869A1 (en) | 2021-03-11 |
| IL277861A (en) | 2020-11-30 |
| WO2019197506A1 (en) | 2019-10-17 |
| JP2021521143A (ja) | 2021-08-26 |
| MA52657A (fr) | 2021-02-17 |
| CN112218895A (zh) | 2021-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202092448A1 (ru) | Axl-специфичные антитела для лечения онкологических заболеваний | |
| EA201791621A1 (ru) | 3-замещенные-1,2,4-оксадиазольные и тиадиазольные соединения в качестве иммуномодуляторов | |
| MX2024000780A (es) | Anticuerpo anti-pd-1 para usarse en el tratamiento de cancer de pulmon. | |
| EA201990997A1 (ru) | Двойные ингибиторы vista и путей pd-1 | |
| CY1125327T1 (el) | Anti-pd-1 αντισωματα και συνθεσεις | |
| EA201791628A1 (ru) | Терапевтические циклические соединения в качестве иммуномодуляторов | |
| EA201991214A1 (ru) | Антитела против pd-1 и их композиции | |
| SA519401522B1 (ar) | Lag-3 أجـسـام مـضـادة لـ وتـركـيـبـات | |
| EA201691376A1 (ru) | Комбинация антагониста pd-1 и ингибитора vegfr для лечения рака | |
| EA202092590A1 (ru) | Пиридазиноны в качестве ингибиторов parp7 | |
| MX2022002682A (es) | Anticuerpos anti-cd73. | |
| EA201791634A1 (ru) | 3-замещенные 1,3,4-оксадиазольные и тиадиазольные соединения в качестве иммуномодуляторов | |
| EA201691487A1 (ru) | Антитела человека к pd-l1 | |
| EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
| EA201791629A1 (ru) | 1,3,4-оксадиазольные и тиадиазольные соединения в качестве иммуномодуляторов | |
| CY1124630T1 (el) | Επιλεκτικη αναγωγη αντισωματων τροποποιημενης κυστεϊνης | |
| EA201691725A1 (ru) | Соединения для лечения опосредованных комплементом нарушений | |
| EA202191784A1 (ru) | Активируемые маскированные связывающие белки к ctla4 | |
| JOP20200157A1 (ar) | أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ cd22 | |
| EA201990530A1 (ru) | Пути применения ингибиторов pd-1/pd-l1 и/или ингибиторов ctla-4 с биологическим средством, содержащим несколько цитокиновых компонентов, для лечения рака | |
| JOP20210164A1 (ar) | طرق وتركيبات علاج السرطان | |
| EA202090746A1 (ru) | Двойные ингибиторы путей tim-3 и pd-1 | |
| EA202090944A1 (ru) | Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его | |
| EA202190588A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| EA202191476A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина |